OYST - Oyster Point Pharma: This Is An Attractive Dry Eye Disease Player For 2020
Today, we will see why Oyster Point Pharma (OYST) is an attractive investment opportunity in 2020.
Company overview
Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative treatments targeting ocular surface diseases. The company’s lead asset is OC-01, an investigational drug candidate and highly selective nAChR (nicotinic acetylcholine receptors agonist). The therapy is being developed as a nasal spray to treat the signs and symptoms of DED (dry eye disease). The company also plans to study OC-01 in NK (neurotrophic keratitis) indication, a degenerative disease in